Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies

June 20, 2024

https://www.prnewswire.com/news-releases/cryoport-and-minaris-regenerative-medicine-form-strategic-partnership-to-support-advancement-of-cell-and-gene-therapies-302177700.html

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products

NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. (“Minaris”), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.